Korro Bio awards SVP 5,500 restricted stock units

Dolan Oliver reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Dolan Oliver reported acquisition or exercise transactions in this Form 4 filing.

Oliver Dolan, Senior Vice President, Finance of Korro Bio, Inc., received a grant of 5,500 shares of common stock issuable upon settlement of restricted stock units on July 15, 2026. These RSUs vest 50% on July 15, 2027 and 50% on July 15, 2028, subject to a continuous Service Relationship. Following this award, he directly holds 23,599 shares, including 16,241 unvested RSU shares scheduled to vest between December 15, 2026 and July 15, 2028.

Insider Trade Summary

Grant/Award: 5,500 shares

Grant/Award 1 txn

Insider Dolan Oliver

Role Senior Vice President, Finance

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	5,500	$0.00	$0.00

Holdings After Transaction: Common Stock — 23,599 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.
2. F2. Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.

Key Figures

RSU grant shares: 5,500 shares of common stock Holdings after transaction: 23,599 shares of common stock Unvested RSU shares: 16,241 shares +4 more

7 metrics

RSU grant shares 5,500 shares of common stock Restricted stock units granted on July 15, 2026 under the 2023 Plan

Holdings after transaction 23,599 shares of common stock Direct holdings of Oliver Dolan following the July 15, 2026 grant

Unvested RSU shares 16,241 shares Shares issuable upon settlement of RSUs that remain unvested after the grant

RSUs vesting on December 15, 2026 10,741 shares Portion of unvested RSUs scheduled to vest on December 15, 2026

RSUs vesting July 15, 2027 2,750 shares Unvested RSUs scheduled to vest on July 15, 2027

RSUs vesting July 15, 2028 2,750 shares Unvested RSUs scheduled to vest on July 15, 2028

Grant vesting structure 50% / 50% New 5,500 RSU grant vests 50% on July 15, 2027 and 50% on July 15, 2028

Key Terms

restricted stock unit (RSU), 2023 Stock Option and Incentive Plan, Service Relationship

3 terms

restricted stock unit (RSU) financial

"shares of common stock issuable upon settlement of a restricted stock unit (RSU)"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

2023 Stock Option and Incentive Plan financial

"RSU granted under the Issuer's 2023 Stock Option and Incentive Plan"

Service Relationship financial

"subject to the reporting person maintaining a continuous Service Relationship"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Korro Bio (KRRO) executive Oliver Dolan receive in this insider transaction?

Oliver Dolan received a grant of 5,500 shares of common stock issuable upon settlement of restricted stock units. The RSUs were granted under Korro Bio’s 2023 Stock Option and Incentive Plan and represent part of his equity-based compensation package.

How do the 5,500 RSUs granted to Korro Bio (KRRO) SVP Oliver Dolan vest?

The 5,500 RSUs vest in two equal tranches: 50% on July 15, 2027 and 50% on July 15, 2028. Each tranche vests only if Dolan maintains a continuous Service Relationship with Korro Bio through the respective vesting date.

What are Oliver Dolan’s total Korro Bio (KRRO) share holdings after this Form 4 transaction?

After the reported grant, Oliver Dolan directly holds 23,599 shares of Korro Bio common stock. This total includes both already-vested shares and shares issuable upon settlement of unvested restricted stock units reported in the filing.

How many of Oliver Dolan’s Korro Bio (KRRO) RSU shares remain unvested and when will they vest?

Dolan’s holdings include 16,241 unvested RSU shares. Of these, 10,741 are scheduled to vest on December 15, 2026, and two tranches of 2,750 shares each are scheduled to vest on July 15, 2027 and July 15, 2028.

Under what plan were the new RSUs to Korro Bio (KRRO) SVP Oliver Dolan granted?

The 5,500 RSUs were granted under Korro Bio’s 2023 Stock Option and Incentive Plan. Shares are issuable upon settlement of the units, subject to the vesting schedule and Dolan’s continued Service Relationship with the company.

Is the Korro Bio (KRRO) RSU award to Oliver Dolan contingent on continued employment?

Yes. Each RSU tranche vests only if Oliver Dolan maintains a continuous Service Relationship with Korro Bio through the applicable dates in 2026, 2027, and 2028. If that relationship ends earlier, unvested RSUs may not settle into shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 07:11 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolan Oliver

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		5,500(1)	A	$0.00	23,599(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issuable upon settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan) that will vest as follows: 50% on July 15, 2027 and 50% on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.

2. Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.

	/s/ Jeffrey Cerio, Attorney-in-fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)